Fingolimod does not enhance cerebellar remyelination in the cuprizone model-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Fingolimod does not enhance cerebellar remyelination in the cuprizone model

Published:2015-08 Issue: Volume:285 Page:180-186
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Alme Maria Nordheim,Nystad Agnes E.,Bø Lars,Myhr Kjell-Morten,Vedeler Christian A.,Wergeland Stig,Torkildsen Øivind

Funder

Novartis

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,Immunology,Immunology and Allergy

Reference32 articles.

1. Demyelination of the superior cerebellar peduncle in the mouse induced by cuprizone;Blakemore;J. Neurol. Sci.,1973

2. Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone;Blakemore;J. Neurol. Sci.,1973

3. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology;Brinkmann;Pharmacol. Ther.,2007

4. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis;Brinkmann;Nat. Rev. Drug Discov.,2010

5. A regenerative approach to the treatment of multiple sclerosis;Deshmukh;Nature,2013

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibiting sphingosine 1-phosphate lyase: From efficacy to mechanism;Neurobiology of Disease;2024-09

2. The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells;Molecular Neurodegeneration;2024-07-12

3. The sphingosine‐1‐phosphate receptor 1 modulator ponesimod repairs cuprizone‐induced demyelination and induces oligodendrocyte differentiation;The FASEB Journal;2024-01-20

4. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis;Pharmacology & Therapeutics;2023-06

5. Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune‐driven demyelination;Clinical & Translational Immunology;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3